Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bulumtatug furvedotin - Mabwell (Shanghai) Bioscience

Next Previous
Search
Drug Profile

Bulumtatug furvedotin - Mabwell (Shanghai) Bioscience

Alternative Names: 9MW-2821; BFv

Latest Information Update: 22 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabwell (Shanghai) Bioscience
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cervical cancer; Urogenital cancer
  • Phase II Triple negative breast cancer
  • Phase I/II Solid tumours
  • Phase I Bladder cancer

Most Recent Events

  • 15 Apr 2025 Mabwell (Shanghai) Bioscience plans a phase I/II trial for Gynaecological cancer (Late-stage disease, Combination therapy) in China in April 2025 (IV, infusion) (NCT06926998)
  • 03 Apr 2025 Mabwell (Shanghai) Bioscience plans a I trial for Triple negative breast cancer (Second-line therapy or greater, Recurrent , Metastatic disease) in May 2025 (IV, Infusion) (NCT06908928)
  • 01 Apr 2025 Mabwell (Shanghai) Bioscience plans a phase I/II trial for Solid tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease) in China (IV) (NCT06947226)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top